Omacetaxine as an anticancer therapeutic: what is old is new again

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Omacetaxine mepesuccinate demonstrated early promise in chronic myeloid leukemia (CML).
• Clinical development was paused due to the introduction of tyrosine kinase inhibitors (TKIs).
• TKI resistance, particularly ABL T315 mutations, has re-ignited interest in omacetaxine for CML.

Purpose of the Study:

• To review omacetaxine's mechanism of action as a protein translation inhibitor.
• To explore its potential efficacy in various cancers, including leukemia stem cells.
• To discuss the clinical significance of omacetaxine's activity against cancer stem cells.

Main Methods:

• Review of existing preclinical and clinical data on omacetaxine mepesuccinate.
• Analysis of omacetaxine's molecular mechanism targeting protein translation.
• Evaluation of studies investigating its role in cancer stem cell eradication.

Main Results:

• Omacetaxine inhibits protein translation, a mechanism with broad anticancer potential.
• The drug has shown activity in hematologic and solid tumors.
• It may possess the ability to eradicate leukemia-initiating cells and other cancer stem cells.

Conclusions:

• Omacetaxine mepesuccinate is a viable therapeutic option for CML patients with TKI resistance.
• Its protein translation inhibition and cancer stem cell targeting capabilities warrant further clinical investigation.
• Omacetaxine may offer a significant clinical benefit in overcoming TKI resistance and improving patient outcomes.